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RNA interference (RNAi) is an established antiviral
defense mechanism in plants and invertebrates.
Whether RNAi serves a similar function in mamma-
lian cells remains unresolved. We find that in some
cell types, mammalian RNAi activity is reduced
shortly after viral infection via poly-ADP-ribosylation
of the RNA-induced silencing complex (RISC), a core
component of RNAi. Well-established antiviral sig-
naling pathways, including RIG-I/MAVS and RNaseL,
contribute to inhibition of RISC. In the absence of
virus infection, microRNAs repress interferon-stimu-
lated genes (ISGs) associated with cell death and
proliferation, thus maintaining homeostasis. Upon
detection of intracellular pathogen-associated
molecular patterns, RISC activity decreases, contrib-
uting to increased expression of ISGs. Our results
suggest that, unlike in lower eukaryotes, mammalian
RISC is not antiviral in some contexts, but rather
RISC has been co-opted to negatively regulate toxic
host antiviral effectors via microRNAs.
INTRODUCTION
RNA interference (RNAi) is a major regulator of gene expression
throughout almost all eukaryotes. The small dsRNA effectors
arise by Dicer processing, and one strand of the duplex becomes
stably incorporated into the multiprotein RNA-induced silencing
complex (RISC). Themechanism bywhich RISC silences a target
mRNA depends on the degree of complementarity between the
small RNA and its binding site. Small interfering RNAs (siRNAs)
typically bind with perfect complementarity and direct RISC-
mediated cleavage of the mRNA (Martinez et al., 2002). Alterna-
tively, miRNAs (derived from endogenous transcripts) typically
bind to the 30 untranslated region (30 UTR) of mRNAs with imper-
fect complementarity. This imperfect base pairing prevents
RISC-mediated cleavage, instead resulting in translation inhibi-
tion and increased turnover of the transcript (Bartel, 2009).
RNAi functions directly as an antiviral defense in some
eukaryotes, including nematodes, plants, and insects. In these
organisms, strong genetic and biochemical evidence exists sup-Cell Hostporting the antiviral role of RNAi (Ding and Voinnet, 2007). First,
mutations of the RNAi machinery render these organisms more
susceptible to virus infection. Second, many viruses known to
infect these cells encode inhibitors of RNAi machinery. Mutation
of these inhibitors causes defects in viral replication that can be
rescued in cells with reduced RNAi activity. Third, siRNAs
derived from viruses are readily detectable (Hamilton and Baul-
combe, 1999) and typically direct cleavage of viral transcripts
(Umbach and Cullen, 2009). Thus, it is widely accepted that
RNAi is an antiviral response in some eukaryotes.
However, in mammalian cells, the antiviral role of RNAi re-
mains controversial (Cullen, 2006; de Vries and Berkhout,
2008; Jeang, 2012; Umbach and Cullen, 2009). There are reports
that mammalian cells defective for RNAi components are more
susceptible to viral replication. However, these data are confined
to a select few viruses that seem to be coincidentally, or possibly
advantageously, regulated by host miRNAs (Cullen, 2006; Lecel-
lier et al., 2005; Otsuka et al., 2007; Umbach and Cullen, 2009).
Additionally, proteins of some mammalian viruses are able to
inhibit RNAi when expressed in noninfectious contexts (Ben-
nasser et al., 2005; Haasnoot et al., 2007; Lecellier et al., 2005;
Li et al., 2004). However, most of these proteins are known to
bind double-stranded RNA as part of well-defined, RNAi-inde-
pendent functions (e.g., virus replication, evading the IFN
response [Umbach and Cullen, 2009]). Significantly, the replica-
tion defects of mammalian viruses with mutant RNA-binding
proteins have not been shown to be rescued in host cells with
defective RNAi. Although transfecting mammalian cells with
synthetic siRNAs clearly inhibits viral replication (Gitlin et al.,
2002), there is little biochemical evidence that natural siRNAs
arise during infection (Lin et al., 2010; Parameswaran et al.,
2010; Pfeffer et al., 2005; Umbach and Cullen, 2009). Therefore,
the role of RNAi during the mammalian antiviral response re-
mains unresolved.
In contrast to lower eukaryotes, mammals possess large-
scale, protein-based innate and adaptive antiviral responses.
The interferon (IFN) response is a key player in this antiviral
defense. Type I IFNs are secreted proteins that, in a paracrine
and autocrine fashion, trigger the expression of hundreds of anti-
viral genes called IFN-stimulated genes (ISGs). Many of these
proteins combat virus infection by stalling the cell cycle, prevent-
ing translation, and promoting cell death (Sadler and Williams,
2008; Schoggins et al., 2011). As might be expected, such
potentially cytotoxic gene products are under multiple layers of
regulation. ISGs are transcriptionally regulated by transcription& Microbe 14, 435–445, October 16, 2013 ª2013 Elsevier Inc. 435
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Figure 1. Triggering the Antiviral Response Inhibits RNAi
(A) Reporter cell lines effectively monitor RNAi. Schematic of Renilla luciferase (RLuc) reporter construct with four perfectly complementary JCV miRNA binding
sites in the 30 UTR is shown (top panel). Firefly luciferase (ffLuc) reporter lacks miRNA binding sites. JM cell lines stably express ffLuc and RLuc reporters and the
JCV miRNA; Mo cell line is identical but lacks the JCV miRNA. Luciferase assays following transfection of JCV and negative control (Neg) anti-miRs confirm
specific regulation of the RLuc reporter (middle). Relative luciferase activity is the ratio of luciferase activity (RLuc/ffLuc) in JCV anti-miR-transfected cells
normalized to Neg anti-miR-treated cells. Northern blot analysis was performed to confirm downregulation of the RLuc reporter mRNA (bottom). GAPDH serves
as a load control.
(B) Triggering the antiviral response with poly I:C inhibits RNAi. RNAi activity was measured by luciferase assay at the indicated times posttransfection with poly
I:C (top). Relative luciferase activity is the ratio (RL/FL) of poly I:C-transfected cells normalized to untreated cells. Northern blot analysis confirms increase in RLuc
reporter mRNA. The appearance of 18S rRNA cleavage fragment is consistent with RNaseL activity (bottom). Bar graphs depict mean; error bars represent SD.
Figure 1 is related to Figure S1.
Cell Host & Microbe
Antiviral Response Inhibits Mammalian RNAifactors, particularly those responsive to JAK/STAT and NF-kB
antiviral signaling pathways. Activation of some ISG products
(e.g., PKR, RNaseL) requires detection of intracellular path-
ogen-associated molecular patterns (PAMPs) by a pattern
recognition receptor (PRR). The translation of at least some
ISG transcripts is regulated posttranscriptionally by miRNAs
(Cloonan et al., 2008; Gregersen et al., 2010; Lee et al., 2012;
Ostermann et al., 2012). Here, we test the hypothesis that anti-
viral signaling in mammalian cells alters the RNAi response,
thereby altering expression of components of the IFN response.
RESULTS
Triggering the Antiviral Response Inhibits RNAi
An antiviral role for mammalian RNAi remains controversial. To
quantitate RNAi activity when antiviral signaling pathways are
activated, we developed stable HEK293 cell lines expressing
luciferase-based reporters (Figure 1A). Specifically, cells were
engineered to coexpress an exogenous miRNA derived from
the JC virus (JCV) alongside short half-life Renilla luciferase
(RLuc) with perfectly complementary binding sites for the JCV
miRNA in its 30 UTR. We previously demonstrated that this
construct is negatively regulated by cleavage of the RLuc
mRNA by RISC (McClure et al., 2011b; Seo et al., 2008). Clonal
lines with varying degrees of repression were obtained, including
JM1 (high) and JM19 (intermediate). Given its larger dynamic
range, we utilized JM1. The parental cell line (mother, ‘‘Mo’’)436 Cell Host & Microbe 14, 435–445, October 16, 2013 ª2013 Elsevlacks the JCV miRNA and expresses only the reporter. We
show that transfection of an anti-miR that specifically inhibits
the JCV miRNA restores luciferase activity in the JM1 line to
the levels of the Mo line (Figure 1A). Northern blot analysis con-
firms that the changes in normalized luciferase signal corre-
spond to the intensity of the RLuc mRNA (Figure 1A, bottom
panel). Thus, we have developed a quantitative assay for RNAi
activity in mammalian cells.
Several PRRs recognize intracellular dsRNA, a common by-
product of viral replication, as a PAMP.We transfected JM1 cells
with poly inosine:cytosine (I:C), amimic of dsRNA. Poly I:C trans-
fection resulted in inhibition of RNAi activity that peaked at 8 hr
posttransfection and lasted the duration of the experiment (Fig-
ure 1B). This treatment had no effect on RLuc expression in the
Mo cell line. Inhibition of RNAi coincides with the induction of
RNaseL activity, as evidenced by cleavage of 18S rRNA (Fig-
ure 1B). In the absence of transfection, treatment of cells with
poly I:C was not sufficient to alter RNAi activity (data not shown).
Competitive binding of the RNAi machinery to poly I:C could
possibly account for the reduced silencing activity. To rule this
out, we transfected a double-stranded miRNA mimic in molar
excess (relative to the amount of poly I:C) and saw no effect on
silencing (Figure S1A). We observed no changes in the level of
key protein effectors of RNAi (Figure S1B), and the addition of
the translation elongation inhibitor cycloheximide affected the
reporter (RLuc) and control (Firefly, FF) luciferase levels nearly
equally (Figure S1C). Taken together, these data indicate thatier Inc.
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Figure 2. Activating the Antiviral Response Inhibits Argonaute-Mediated Cleavage via Poly-ADP-Ribosylation of RISC-Associated Proteins
(A) Schematic of the canonical miRNA biogenesis pathway (left panel). Northern blot analysis shows that steady-state levels of Dicer products are unaffected by
poly I:C transfection (right). Ethidium bromide-stained, low-molecular-weight RNA serves as a load control.
(B) Schematic of Ago2 substrate pre-miR-451 and the derivative Ago2 cleavage product (left). Radiolabeled pre-miR-451 was incubated with HEK293 cellular
extracts and resolved by denaturing PAGE. Immunodepletion of Ago2 results in decreased product. Preimmune IgGwas used as a control (middle). Lysates from
cells transfected with poly I:C for 8 hr show reduced RISC-mediated cleavage of pre-miR-451 (right). Probe alone (P.A., no lysate added) and mock transfected
lysates were used as a control. Immunoblots confirming levels of Ago2 and b-actin are shown below.
(C) pADP-r modification of RISC-associated proteins. Lysates were prepared from cells treated with sodium arsenite (positive control), transfected with poly I:C,
or mock treated (M). Ago2 was immunoprecipitated (preimmune IgG used as control, lane 1). Bound fraction was immunoblotted with pADP-r antibody.
Immunoblot for Ago2 was performed as a control. pADP-r-modified proteins are indicated with a bracket.
(D) Analysis of RNAi activity in the presence of a PARP inhibitor. RNAi activity was assayed using JM1 cells transfected with poly I:C and/or treated with 20 mM
3-aminobenzamide (3-AB), a general PARP inhibitor.
(E) Role of PARP13 in poly I:C-mediated RNAi Inhibition. RNAi activity was assayed using JM1 cells following transfection of siRNAs and poly I:C. Relative
luciferase activity is normalized to untreated reporter cells. siRNA knockdown of PARP13 was confirmed by immunoblotting (shown below). Bar graphs depict
mean; error bars represent SD.
Cell Host & Microbe
Antiviral Response Inhibits Mammalian RNAithe inhibition of RNAi was not due to a nonspecific block of trans-
lation. Furthermore, RNAi inhibition was not unique to one spe-
cific reporter or miRNA.We observed similar effects in a different
RNAi reporter cell line expressing the exogenous Merkel Cell
Polyomavirus miRNA and corresponding RLuc reporter (Seo
et al., 2009) (Figure S1D). Additionally, cells transiently trans-
fected with plasmids expressing the JCV miRNA and a reporter
subject to cleavage-independent repression showed decreased
repression when cotransfected with poly I:C (Figure S1E). These
results demonstrate that the inhibition of RNAi is not restricted to
RISC-mediated mRNA cleavage. We conclude that detection of
intracellular poly I:C leads to a previously uncharacterized inhibi-
tion of RNAi in mammalian cells.
Poly I:C Triggers Poly-ADP-Ribosylation and Inhibition
of RISC
Transfection of poly I:C resulted in inhibition of RNAi (Figure 1B).
To determine which component(s) of the RNAi machinery were
inhibited, we first performed northern blot analysis on theCell Hosteffector RNAs. The steady-state levels of neither exogenous
(JCV miRNA 5p or 3p derivatives) nor endogenous (miR-let7)
miRNAs were altered (Figure 2A). As steady-state levels of Dicer
products were unaffected by poly I:C, we predicted that a down-
stream component of RNAi is inhibited by mammalian antiviral
signaling.
RISC functions downstream of Dicer. Therefore, we sought to
determine whether human Argonaute2 (Ago2), a key component
of RISC, is inhibited by antiviral signaling. We adapted an in vitro
RISC cleavage assay from zebrafish (Cifuentes et al., 2010).
Treatment of substrate RNA with cell lysate resulted in specific
cleavage (Figure 2B). Immunodepletion of Ago2 confirms the
specificity of our assay (Figure 2B, left panel). Lysate prepared
from cells transfected with poly I:C was defective in RISC-medi-
ated cleavage activity (Figure 2B, right panel), demonstrating
that poly I:C-mediated effects inhibit RISC.
Recently, Leung and colleagues demonstrated that treat-
ment of cells with oxidative and other stressors induced poly-
ADP-ribosylation (pADP-r) of human Ago1–Ago4, relieving& Microbe 14, 435–445, October 16, 2013 ª2013 Elsevier Inc. 437
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Figure 3. Viral Infection Inhibits RNAi Activity via Poly-ADP-Ribosylation of RISC-Associated Proteins
(A) RNAi activity was assayed in JM1 cells infected with HSV-1, Sendai, or WT Influenza A (Flu WT), or an NS1 mutant Influenza A (S42D) (Flu mt). Relative
luciferase (RL/FL) is normalized to mock infected cells.
(B) In vitro RISC cleavage is inhibited following HSV-1 infection. Radiolabeled pre-miR-451 was incubated with cellular extracts prepared from HSV-1-infected
HEK293 cells at 3 and 6 hr postinfection. Lysate from mock infected (M) or probe alone (P.A.) are shown as controls. Immunoblot confirms similar Ago2 protein
levels following infection (below).
(C) pADP-r modification of RISC-associated proteins from virus-infected cells. Ago2 immunoprecipitated from cells was infected as indicated. Bound fraction
was immunoblotted with pADP-r antibody. Immunoblot for Ago2 was performed as a control. pADP-r-modified proteins are indicated with a bracket.
(D) pADP-r modification of PARP13-associated proteins. HEK293 cells were infected as indicated. PARP13 was immunoprecipitated and the bound fraction was
immunoblotted for pADP-r. Immunoblot for PARP13 was performed as a control.
(E) Ago2 and PARP13 interact in virus-infected cells. HEK293 cells were infected as indicated and Ago2 was immunoprecipitated. Bound fractions were
immunoblotted for PARP13 (and Ago2 as a control).
(F) PARP inhibitor blocks virus-induced inhibition of RNAi. Luciferase assay was performed using JM1 cells infected with HSV-1 treated with 20 mM 3-AB.
Relative luciferase activity is normalized to untreated reporter cells. Bar graphs depict mean; error bars represent SD. Figure 3 is related to Figure S2.
Cell Host & Microbe
Antiviral Response Inhibits Mammalian RNAimiRNA-mediated repression (Leung et al., 2011). Given that viral
infection can trigger stress responses, we asked if the decreased
RISC activity that we observe could be associated with pADP-r
of Ago. We immunoprecipitated Ago2 followed by immunoblot
against pADP-r-modified proteins. Consistent with Leung
et al., we observed a basal amount of pADP-r-modified proteins
in the Ago2 immunoprecipitate (Figure 2C, lane 2). However,
upon transfection of poly I:C, a profound increase in the amount
of pADP-r-modified proteins was detected in the Ago2 immuno-
precipitate. The degree of poly-ADP-r observed here is on par
with the reported effects of treatment with the oxidative stressor
sodium arsenite (Leung et al., 2011; Figure 2C). We next deter-
mined if poly-ADP-ribose polymerase (PARP) activity was
required for antiviral signaling-dependent relief of RNAi. Per-
forming our RNAi activity assay in the presence of a chemical in-
hibitor of PARP (3-Aminobenzamide, 3-AB) resulted in less poly
I:C-induced inhibition of RNAi (Figure 2D). Leung et al. demon-
strated that the cytoplasmic PARP13 is a key component of
stress-induced relief of RISC activity (Leung et al., 2011). Inhibi-438 Cell Host & Microbe 14, 435–445, October 16, 2013 ª2013 Elsevtion of RNAi activity in response to poly I:C was prevented
following siRNA-mediated knockdown of PARP13 (Figure 2E).
Combined, these results show that triggering the mammalian
intracellular antiviral response results in pADP-r of Ago2 and/or
its associated proteins and that inhibition of RISC activity is at
least partly dependent on PARP13.
Infection with Viruses that Activate the Antiviral
Response Inhibits RNAi
We next asked whether infection with virus inhibited mammalian
RNAi. We chose two different viruses known to elicit antiviral
signaling: herpes simplex virus 1 (HSV-1), a DNA virus; and
Sendai virus (SenV), an RNA virus. To probe the import of the
antiviral response in inactivating RNAi, we also used a mutant
influenza A virus (Flu mt) that induces an increased antiviral
response compared to the wild-type virus (Flu WT) (Hale et al.,
2008; Hsiang et al., 2012). Infection with HSV-1, SenV, and Flu
mt resulted in reduced RISC activity (Figure 3A), while infection
with Flu WT only minimally relieved RISC activity. These dataier Inc.
A 
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Figure 4. MAVS andRNaseLContribute to Poly-ADP-Ribosylation of
RISC-Associated Proteins
pADP-r modification of RISC-associated proteins is reduced in MAVS and
RNaseL knockout MEFs. Ago2 was immunoprecipitated from MEF knockout
cell lines either mock (M) infected or infected with HSV-1. Bound fractions
were immunoblotted for pADP-r (and Ago2 as a control). Figure 4 is related to
Figure S3.
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Antiviral Response Inhibits Mammalian RNAidemonstrate that the inhibitory effect on RISC is due to activation
of the host antiviral signaling, rather than being a result of viral
gene products directly blocking RISC. Infection of the Mo cell
line with any of the four viruses had no effect on reporter-specific
expression (data not shown). In vitro cleavage assays confirmed
that infection with HSV-1 inhibits Ago2-mediated cleavage (Fig-
ure 3B). Furthermore, proteins associated with immunoprecipi-
tated Ago2 displayed increased pADP-r in response to infection
with HSV-1, SenV, or Flu mt but not with Flu WT (Figure 3C).
PARP13-associated proteins are also poly-ADP-ribosylated in
response to infection with Flu mt or HSV-1 (Figure 3D). Further-
more, PARP13 is observed in greater association with Ago2
upon infection (Figures 3E and S2A), and transfection of a
plasmid expressing PARP13 augments the inhibitory effects of
poly I:C on RNAi (Figure S2B). Our data show an increased asso-
ciation between PARP13 and Ago2. These findings connect
PARP13 activity and association with Ago2 activity, providing
evidence of a regulatory role for PARP13 in RISC function during
viral infection. To determine if pADP-r is required for viral-medi-
ated relief of RISC activity, we treated our RNAi reporter cells
with the pADP-r inhibitor 3-AB during infection with HSV-1.
Treatment with 3-AB suppressed the RNAi relief observed with
HSV-1 infection (Figure 3F), correlating in degree with the
amount of pADP-r detected on Ago2-associated proteins (Fig-
ure S2C). Therefore, we conclude that the response of mamma-
lian cells to infection by diverse viruses involves pADP-r of
PARP13- and Ago2-associated proteins, with the latter resulting
in reduced RNAi activity.
Antiviral Signaling Pathways Contribute to Inhibition
of RISC
Next, we investigated what components of the antiviral response
are important for relief of RISC-mediated repression. Treatment
with IFN was not sufficient to relieve repression by RISC, but
augmented the effect of poly I:C (Figure S3A). Mitochondrial anti-
viral signaling adaptor (MAVS) and RNaseL are both indirectly
activated by dsRNA. Using a genetic approach, we tested
whether these pathways have a role in inhibition of RNAi. Mouse
embryo fibroblast (MEF) cell lines devoid of MAVS or RNaseL
both show reduced pADP-r of Ago2-associated proteins upon
infection with HSV-1 (Figure 4). siRNA-mediated knockdown of
MAVS in JM1 cells decreases poly I:C-induced inhibition of
RISC activity (Figure S3B). RIG-I is a PRR that binds to dsRNA
and activates MAVS. To determine if activating MAVS was
sufficient to inhibit RNAi, we expressed an amino-terminal frag-
ment of RIG-I capable of activating MAVS in the absence of
dsRNA (Saito et al., 2007). This failed to inhibit RNAi; how-
ever, it substantially augmented the effects of poly I:C (Fig-
ure S3C). These data show that different PRRs can indirectly
contribute to the repression of RISC during the antiviral
response, but that this inhibition requires intracellular detection
of a dsRNA PAMP.
Cytotoxicity-Associated ISGs Are Particularly Amenable
to miRNA-Mediated Regulation, which Is Alleviated by
Inhibition of RISC during the Antiviral Response
The question arises as to what benefit (if any) mammalian cells
receive from inhibiting RISC during viral infection. pADP-r of
RISC-associated proteins leads to inhibition of both siRNA-Cell Hostmediated cleavage and miRNA-mediated repression (Leung
et al., 2011; Figures 2, 3, and S2). We hypothesized that relief
of miRNA-mediated regulation could allow for enhanced transla-
tion of the host mRNAs that are highly regulated by miRNAs.
Many ISGs are toxic to cells (Barber, 2000), and cytotoxic
gene products are typically subject to multiple layers of regula-
tion. Therefore, we predicted that, compared to all mRNAs,
miRNAs and RISC are more likely to regulate the expression of
ISGs. To determine the likelihood that miRNAs regulate the IFN
response, we first utilized a bioinformatic approach based
on literature-annotated ISGs (http://www.lerner.ccf.org/labs/
williams/isgd.cgi) and the TargetScan miRNA target prediction
software (Lewis et al., 2005). The 30 UTRs of transcripts are the
predominant docking sites of the miRNA-RISC complexes, and
our results show that, as a whole, ISG 30 UTRs have an approx-
imately 2-fold higher median of predicted evolutionarily
conserved miRNA binding sites, compared to all 30 UTRs (Fig-
ure 5A). Strikingly, when only those 136 ISGs annotated as asso-
ciated with cell death and proliferation (Huang et al., 2009; Table
S2) were analyzed, this difference increased to 4-fold. Thus,
although these analyses revealed an underrepresentation of
miRNA binding sites in some (especially canonical) ISGs (data
not shown), these analyses do strongly support the hypothesis
that some ISGs, especially those associated with toxicity, are
particularly susceptible to miRNA-mediated regulation.
Next, we experimentally identified those ISG transcripts that
are most susceptible to miRNA-mediated regulation. To do
this, we took advantage of a human colorectal cancer cell
line (DLD-1) with an engineered hypomorphic mutant Dicer
(ex5/) leading to reduced miRNA levels (Cummins et al.,
2006). These cells, and the corresponding WT parental cells,
were treated with type I IFN and subjected to microarray-based
analysis of mRNA expression. A number of ISG transcripts are
expressed at higher levels in the ex5/ cells (Figures S4A,
S4B, and data not shown), demonstrating that a subset of these
mRNAs are regulated by RNAi machinery.& Microbe 14, 435–445, October 16, 2013 ª2013 Elsevier Inc. 439
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Figure 5. miR-17/93 Family Regulates IFN-Stimulated Genes and Promotes HSV-1 Infectivity
(A) Analysis of conserved miRNA targets predicted by TargetScan. The median number of predicted, conserved miRNA binding sites per 30 UTR was calculated
for all human genes (All), ISGs, the Defense Response and Response to Virus (v-Defense) subgroup, and the Regulation of Cell Death and Regulation of Cell
Proliferation (Death/Prolif) subgroup.
(B) Sylamer heptamer analysis of rank-ordered microarray data from pretreatment of DLD-1 WT and Dicer ex5/ cell lines at the indicated times. miR-17/93
family heptamer is highlighted in blue. Red line represents the threshold for a Bonferroni corrected E-value of 0.05.
(C) Analysis of miR-17 family miRNAmimics on HSV-1 infection. Dicer hypomorph cells were transfected with the indicatedmiRNAmimics. After 24 hr, cells were
treated with 1,000 U/ml of universal type 1 IFN for 3 hr prior to infection with HSV-1. The media were collected 48 hr postinfection and virus was titered via plaque
assays. A representative plaque assay is shown (left panel). Results from three independent infections were quantified (right).
(D) IRF9 30 UTR is derepressed following poly I:C transfection. Schematic of the full-length IRF9 30 UTR reporter construct is shown (top). HEK293T cells were
cotransfected with RLuc and ffLuc reporters and miRNAmimics. Twenty-four hours later, cells were transfected with poly I:C and harvested for luciferase assays
after 8 hr. Relative fold repression of luciferase activity (RL/FL) is determined by normalizing miR-17 or miR-93 mimic-transfected cells to the irrelevant miRNA
mimic-transfected control cells. Bar graphs depict mean; error bars represent SD. Figure 5 is related to Figure S4.
Cell Host & Microbe
Antiviral Response Inhibits Mammalian RNAiThe 50 end of a miRNA (nucleotides 2–8), referred to as the
‘‘seed’’ region, plays a critical role in targeting transcripts. To
determine if any of the ISG mRNAs identified above were
enriched for specific miRNA seed complements, we conducted
Sylamer bioinformatic analysis (van Dongen et al., 2008) on tran-
scriptsmore highly expressed in the ex5/ cells, relative toWT,
following IFN treatment. Those transcripts that are more highly
expressed in the ex5/ hypomorph after IFN treatment are
shown to contain significantly more binding sites for the miR-
17/93 family (Figure 5B).
To determine if, as our results would predict, ISG transcripts
are bona fide targets of the miR-17/93 family, we conducted a
meta-analysis of published miRNA target lists identified from
RISC-bound transcripts (Gottwein et al., 2011; Riley et al.,440 Cell Host & Microbe 14, 435–445, October 16, 2013 ª2013 Elsev2010; Skalsky et al., 2012). Gottwein et al. and Skalsky et al. uti-
lized PAR-CLIP, while Riley et al. utilized HITS-CLIP-based stra-
tegies to identify global miRNA target sites. Our analysis showed
that many of the miR-17/93 family targets identified in these
studies are annotated as ISGs (Figure S4C). Despite not being
saturated, and being conducted in different lines of B cells,
several ISGs were identified as targets of miR-17/93 in two or
more of these studies. Next, we took an independent bio-
informatic approach and interrogated the CLIP data sets to ask
what miRNAs were most associated with the literature-anno-
tated ISG transcripts (http://www.lerner.ccf.org/labs/williams/
isgd.cgi). Several different miRNAs, including miR-548 and
miR-142, were identified in two more of the studies (Figure S4D).
These data argue that multiple different miRNAs play a role inier Inc.
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fied the miR-17/93 family as having the most interactions with
ISG transcripts (Figure S4D). Together, our results using
different cell types and completely different methodologies
demonstrate that, while not the only miRNA family to target
ISGs, the miR-17/93 family plays an especially important role
in regulating them.
To test a functional role for the miR-17/93 family miRNAs in
negatively regulating ISGs, we transfected the Dicer hypo-
morph DLD-1 cells with synthetic mimics of miR-17, miR-93,
or any of several additional control and host miRNAs. Following
3 hr of treatment with type I IFN, sufficient time for ISG tran-
scription, we then infected with HSV-1 or Flu mt. Production
of new virus was measured 48 hr postinfection. Consistent
with the notion that miR-17/93 negatively regulates compo-
nents of the antiviral response, we observed a reproducible
2- to 3-fold increase in secreted virus from cells expressing
miR-17 or miR-93, but not the control miRNA mimics (Figures
5C and S4E). Similar results of slightly less magnitude were
observed without IFN pretreatment (data not shown). Recent
in vivo work shows that Dicer hypomorphic mice controlled viral
infection better than wild-type mice at early times postinfection
(Ostermann et al., 2012). This observation could be explained
by the effects of miR-17/93 (or similar-functioning miRNAs) on
ISG expression. Combined, these observations support an indi-
rect role for miRNAs in promoting infection in cells undergoing
an IFN response, by suppressing the translation of some ISG
mRNAs.
Our data show miRNAs negatively regulate cytotoxic ISG
expression. Thus, miRNAs can be considered proviral in some
contexts. Consequently, we hypothesized that mammalian cells
alleviate RISC to allow for increased ISG expression. We tested
whether initiating the antiviral response can relieve repression of
a well-established ISG transcript targeted by miR-17/93. IRF9 is
a sometimes procytotoxic (Tsuno et al., 2009) transcription fac-
tor that plays a central role in the activation of promoters contain-
ing IFN-stimulated responsive elements (ISREs) (Mu¨ller et al.,
1993). Thus, IRF9 is atypical, being both an ISG itself and also
a transactivator of numerous other ISGs (Tsuno et al., 2009).
Our analyses of both DLD-1 and B cells identified it as a target
of miR-17/93 (Figures S4B and S4C and data not shown). First,
we confirmed that endogenous IRF9 protein levels were higher
in DLD-1 dicer hypomorph cells undergoing an IFN response
(Figure S4F). Although unchanged at 4 hr post-IFN treatment
(data not shown), at 6, 8, and 10 hr post-IFN treatment, IRF9 pro-
tein levels were higher in the hypomorphs (Figure S4F). Next, we
cloned the entire 30 UTR of human IRF9 behind a luciferase re-
porter to determine if it is regulated by either miR-17 or miR-93
in HEK293T cells. Compared to an irrelevant control miRNA,
both miR-17 and miR-93 repressed luciferase activity by 1.7-
fold (Figure 5D, left side). When we performed the same experi-
ment following transfection of poly I:C, we observed reduced
miRNA-mediated repression (Figure 5D, right side), as would
be predicted from our above results (Figures 1B, S1D, and
S1E). These data show that triggering the antiviral response
can alleviate miRNA-mediated posttranscriptional regulation of
an antiviral transcript. Combined, the above data demonstrate
that increasing the activity of the miRNA arm of the RNAi
response can be proviral in mammalian cells and, conversely,Cell Hostinhibiting miRNA activity can increase the protein-mediated anti-
viral response.
DISCUSSION
RNAi is an essential antiviral defense against viruses in plants
and invertebrates. However, whether RNAi plays a similar role
in mammalian cells remains debated. Here, we provide evidence
that antiviral signaling attenuates RISC activity in different types
of somatic mammalian cells. After viral infection, or treatment
with poly I:C, RISC-associated proteins become posttranslation-
ally modified with pADP-r. Consistent with the findings of Leung
and colleagues (Leung et al., 2011), we show increased pADP-r
of RISC correlates with decreased siRNA and miRNA silencing
activities (Figures 2C and 3C). We demonstrate that the MAVS
and RNaseL pathways are involved at least indirectly in virus-
mediated inhibition of RNAi (Figures 4 and S3) and speculate
that these pathways may serve to induce the levels of PARP or
other factors required for ADP-ribosylation of RISC. Thus, we
have identified an additional biological trigger that leads to
pADP-r-mediated inhibition of RISC. pADP-r of RISC correlates
with an increased association between PARP13 and the RISC
complex (Figures 3E and S2A). Despite being catalytically inac-
tive, PARP13 was shown to be an essential hub for fostering
the interaction of various PARPs with RISC (Leung et al., 2011).
Together, these data suggest that antiviral signaling leads to
both increased PARP13 association with and pADP-r of RISC,
resulting in reduced RNAi activity.
Our results are consistent with an earlier report showing that
HSV-1 infection can inhibit RNAi (Wu et al., 2009). While no
mechanism was provided for this observation, it was suggested
that undefined, virus-encoded effectors blocked RNAi to evade
its role as an antiviral defense. Previous reports have shown
that infection with HSV-1 produces dsRNA (Weber et al., 2006)
and elicits an antiviral signaling response (Melchjorsen et al.,
2010; Rasmussen et al., 2009). Therefore, we predict that the
HSV-1-mediated inhibition of RNAi is at least partly due to acti-
vation of the antiviral response (Figure 4). Consistent with this,
infection with either Sendai virus, which is known to elicit an anti-
viral response (Seth et al., 2005), or a mutant influenza virus,
known to have an enhanced antiviral response (Hale et al.,
2008; Hsiang et al., 2012), results in ADP-ribosylation of RISC
and inhibition of RNAi (Figure 3). Minimally, we show that infec-
tion with diverse viruses capable of triggering antiviral signaling
responses results in diminished RNAi activity in mammalian
cells. Combined with the difficulty of identifying siRNAs in
virus-infected mammalian cells (Lin et al., 2010; Parameswaran
et al., 2010; Pfeffer et al., 2005; Umbach and Cullen, 2009) and
the lack of strong genetic evidence, our results argue that, at
least for some cells, canonical RNAi is not an antiviral response
in mammals.
What advantage is there to mammalian cells in attenuating
RNAi during the antiviral response? Unlike plants and inverte-
brates, mammals have evolved an elaborate protein-based
antiviral defense that is controlled by multiple layers of nega-
tive regulation. Once intracellular pathogens are detected,
dispensing with such regulation would help ensure a robust
response to infection. We demonstrate that ISGs, particularly
those associated with cell proliferation and cell death, are& Microbe 14, 435–445, October 16, 2013 ª2013 Elsevier Inc. 441
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Figure 6. Model: Different Roles of RNAi Machinery in Somatic
Mammalian Cells versus Plants and Invertebrates.
RNAi directly blocks viral replication in plants and invertebrate animals (top).
RNAi and RISC components in somatic mammalian cells repress expression
of ISG/antiviral effectors via miRNAs. RNAi is inhibited by activation of the
intracellular antiviral response, allowing for optimal ISG expression, especially
of cytotoxic ISGs (bottom).
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ThemiR-17/93 family of miRNAs can negatively regulate compo-
nents of the antiviral response in diverse cell types (Figures 5B,
S4C, and S4D). Consistent with this, it has previously been
reported that exogenous expression of miR-93 is proviral (San-
thakumar et al., 2010). Despite the clear role of miR-17/93 in
regulating the antiviral response, we note that our data (Fig-
ure S4D) and others’ published work (Cloonan et al., 2008;
Gregersen et al., 2010; Lee et al., 2012; Ostermann et al.,
2012) indicate that additional miRNAs are also involved in regu-
lating ISGs. This point is particularly relevant to nondividing and
nontransformed cells where miR-17-related miRNAs are typi-
cally not abundantly expressed.
Combined, our data support the following model (Figure 6): In
many eukaryotes, RNAi serves as a primary antiviral defense by
directing the RISC machinery to cleave viral RNAs, thereby hin-
dering infection. However, the evolution of a large-scale, protein-
based antiviral defense has produced an effective alternative for
combating viral infection without RNAi. In somatic cells of mam-
mals (and possibly cells of other jawed vertebrates), several
different miRNAs and the RNAi machinery have been co-opted
to negatively regulate expression of many of the cytotoxic effec-
tors of this protein response, thereby allowing for responsive
control of its timing, degree, and resolution. Within this model,
we predict that cells receiving only transient extracellular stimu-
lation of the IFN receptor will express ISG transcripts to prepare442 Cell Host & Microbe 14, 435–445, October 16, 2013 ª2013 Elsevfor a possible infection and that miRNAs will contribute to
recovery from this IFN response. We note that, as miRNAs are
endogenous products of the RNAi machinery, this model allows
for some RNAi components to be considered proviral under
certain IFN-rich conditions. If, however, the appropriate intracel-
lular PRRs are activated, miRNA activity is reduced through
posttranslational modification of RISC. This inhibition of RNAi
allows enhanced expression of ISGs, resulting in increased cell
death. Similar to a grenade requiring two triggers to detonate
(pull the pin; release the handle), IFN signaling and inhibition of
RISC combine to produce a robust, terminal IFN response.
Several reports have indicated different immunostimulatory
extracellular cues can induce the expression of various miRNAs
(O’Connell et al., 2007; Taganov et al., 2006). We propose that
these miRNAs promote an antiviral state in certain contexts,
or, in other cases, serve as part of a negative feedback loop to
quench the antiviral response if subsequent intracellular infec-
tion is not detected.
There are several important implications of this model. First,
our work suggests that ‘‘canonical’’ RISC-dependent RNAi is un-
likely to be an antiviral effector in cells with a strong IFN-based
response, including somatic cells of mammals and other verte-
brates. We note that this does not rule out a possible role for
RNAi in defending against viruses in some other cell types that
have a reduced IFN response (e.g., mammalian embryonic
stem cells [Chen et al., 2010]).
Second, there exists an emerging model that diverse viruses
utilize viral and possibly host-derived miRNAs to control the
switch from latent/persistent infection to lytic/productive replica-
tion (Gunasekharan and Laimins, 2013; Kincaid and Sullivan,
2012; Murphy et al., 2008). Since it is now clear that various
stressors can elicit pADP-r modification of RISC-associated pro-
teins, our model suggests that these viruses could take advan-
tage of changes in miRNA regulatory activity as a barometer
for cellular stress. This could represent one mechanism for
how these viruses promote ‘‘release’’ from miRNA-reinforced
latency under stress conditions (e.g., a secondary infection acti-
vates the antiviral signaling pathway, inactivating RISC). Some
viruses utilize miRNA activity during productive/lytic infection.
Our model predicts that these viruses block antiviral signaling,
thereby preventing inhibition of RISC, or that the degree of
residual RISC activity is sufficient for the relevant silencing
activity. We note that our model in no way precludes an antiviral
role for miRNAs in certain contexts. For example, pox virus infec-
tion ablates host miRNA activity, likely to avoid direct negative
regulation of its own transcripts (Backes et al., 2012). In such
situations, we suggest that the benefits to the virus of removing
host miRNA function outweigh the costs of any possible
increased toxic ISG response.
Third, while our ‘‘grenademodel’’ focuses on control of the IFN
response, it also applies, in principle, to other stress responses
reliant on expression of cytotoxic proteins. For example, severe
oxidative damage could attenuate miRNA-mediated repression
to increase the amount of and/or the speed with which heavily
regulated cytotoxic effectors are made. Interestingly, some
ISGs, including those that are cytotoxic, are also induced by
other stress stimuli (Chawla-Sarkar et al., 2003). The ability of
separate pathways to converge on the same cytotoxic genes
both underscores the importance of careful regulation andier Inc.
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signals from independent signaling cascades. Consistent with
this, miRNAs have been implicated in maintaining diverse
cellular processes of homeostasis (Ebert and Sharp, 2012;
Mendell and Olson, 2012).
In summary, we show that antiviral signaling leads to an inhib-
itory pADP-r modification of RISC-associated proteins. Inhibition
of RISC leads to derepression of a subset of ISG transcripts.
Therefore, we conclude that, in some contexts, components of
the mammalian RNAi pathway do not play an antiviral role. On
the contrary, miRNAs and the RNAi apparatus have been co-
opted to negatively regulate toxic effectors of the protein-based
IFN response.
EXPERIMENTAL PROCEDURES
Detailed methods are included in Supplemental Information.
Cell Culture and Reagents
Mo and the JM1 cell lines are HEK293 derivatives that stably express the RLuc
RNAi reporter with (JM1) or without (Mo) the exogenous JC virus miRNA
(McClure et al., 2011b). These and the MEF and DLD-1 cell lines and deriva-
tives were grown under ATCC-recommended conditions. Commercial
sources for chemicals and antibodies are listed in Supplemental Experimental
Procedures.
Plasmid Constructs
All constructs were cloned using standard molecular biology procedures. See
Supplemental Experimental Procedures for details and custom oligonucleo-
tides used.
RNAi Activity Reporter Assay
Mo or JM1 cells were assayed with the Dual-Glo Luciferase Assay System.
Poly I:C treatment: Cells were transfected with 0.5 mg poly I:C using the Lipo-
fectamine 2000 reagent (Invitrogen) and harvested 8 hr after transfection, un-
less otherwise noted. Cells were infected with HSV-1 (moi 10), harvested 10 hr
postinfection; influenza virus A wild-type (Flu WT) and Flu mt S42D (Hsiang
et al., 2012) (moi 2), harvested 13 hr postinfection; or Sendai 50 HA/ml, har-
vested 6 hr postinfection. RIG-I CARD domain: The amino-terminal domain
CARD domain construct (Saito et al., 2007) was provided by M. Gale (Univer-
sity of Washington). JM1 cells were transfected with either control pcDNA3.1
or pcDNA3.1 RIG-I CARD using Lipofectamine 2000. Forty hours posttransfec-
tion, cells were transfected with 0.5 mg poly I:C. ISG15 induction was assayed
via standard semiquantitative RT-PCR with control for linearity. See Supple-
mental Experimental Procedures for primers and amplification conditions.
Monitoring miRNA Activity
HEK293T cells were transiently transfected with reporters and various miRNA
mimics. Eighteen hours posttransfection, cells were either treated with 250 mM
sodium arsenite (90 min) or transfected with poly I:C followed by luciferase
assay.
Northern Blot Analysis
Total RNA was run on denaturing PAGE gels, transferred to membranes,
probed with radiolabeled oligonucleotide probes, and visualized via film on
Phosphorimager (McClure et al., 2011a; Seo et al., 2008).
siRNA Knockdowns
Knockdown of irrelevant controls (eGFP, GAPDH), PARP13, or MAVS was
achieved through double transfection (repeat siRNA transfection after 48 hr)
of 20 nM siRNAs (Table S1). Forty-eight hours after second transfection, cells
were transfected with poly I:C and assayed for luciferase activity 8 hr later.
Western Blot Analysis
Proteins were extracted using cell lysis buffer consisting of 50 mMHEPES (pH
7.4), 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 1% Triton X-100, 1 mM DTT,Cell Hostand the complete EDTA free protease inhibitor cocktail (Roche). Lysates
were size fractionated by SDS-PAGE and immunoblotted with antibodies.
See Supplemental Experimental Procedures for details of antibodies used.
In Vitro RISC Mediated Cleavage Assay
Cell extracts were exposed to a synthetic Ago2 radiolabeled substrate pre-
miR-451, separated on a denaturing PAGE gel and visualized on a Phosphor-
imager (Cifuentes et al., 2010).
Detection of the Poly-ADP-Ribosylation of Ago2
Poly I:C-treated and infected extracts were immunoprecipitated for Ago2,
and associated proteins were immunoblotted for Ago2, PARP13, or pADP-r-
modified proteins (Leung et al., 2011).
Role of miR-17/93 in Virus Infection
DLD-1 Dicer hypomorph cells were transfected with miRNA mimics. Cells
were treated with IFN and then infected with HSV-1 or Flu mt. Secreted infec-
tious virus concentration was determined via plaque assay.
Microarray Analysis
Total RNA was harvested from IFN-treated DLD-1 WT and DLD-1 Dicer hypo-
morph cells. Illumina HumanHT-12 v4.0 microarray mRNA analysis identified
transcripts higher in IFN-treated miRNA hypomorph cells. Sylamer analysis
identified transcripts with 30 UTRs significantly enriched for miRNA comple-
mentary sites (van Dongen et al., 2008).
Analysis of ISG 30 UTRs and Predicted miRNA Target Sites
ISG names were obtained from the ISG database of Bryan Williams (http://
www.lerner.ccf.org/labs/williams/isgd.cgi). Median 30 UTR length was ex-
tracted from TargetScan 6.2 30 UTR sequence alignment (Lewis et al., 2005).
Counts of miRNA target sites were generated for each gene. Conservation
of miRNA families and conservation of miRNA target sites was defined accord-
ing to the TargetScan 6.2 database. G.O. analysis of the ISGs used DAVID
(Huang et al., 2009). Functional annotation charts were generated using the
GOTERM_BP_FAT category of terms.
Meta-Analysis of Published miRNA Target Profiles
Targets were extracted from three CLIP data sets (Gottwein et al., 2011; Riley
et al., 2012; Skalsky et al., 2012), and the ISG target subset was identified bio-
informatically (custom python scripts). miRNA families enriched for targeting
ISGs were derived from counts of CLIP-identified targets.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.chom.2013.09.002.
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